Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Avlayah Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Enzyme and Metabolic Disorder Therapies: Avlayah (tividenofusp alfa-eknm)

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs MassHealth prior authorization under the medical benefit for continued treatment with Avlayah for eligible members with Hunter syndrome, including members new to the plan and members continuing established therapy.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyAvlayah continuation therapy
    Policy CodePolicy N/A
    Change TypeAdministrative formatting update
    Effective DateJan 4, 202748d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization under the MassHealth UPPL; Avlayah is covered under the medical benefit.
    SourceLink
    POLICY UPDATE CHANGES

    The review history states that the policy formatting was updated.

    AvlayahCovered therapy
    MedicalBenefit
    Prior authorizationRequirement
    12 monthsInitial approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Reauthorization
    ≥ 5 kgMinimum weight

    Coverage Criteria

    Continuation therapy

    Authorization may be granted under either pathway below.

    Continuation authorization pathways

    • New-to-plan continuation: The member is new to the plan, as evidenced by a coverage effective date of less than or equal to 90 days, and medical records document current treatment with the requested drug.Coverage effective date ≤ 90 days

      Treatment obtained as samples or through a manufacturer's patient assistance program does not satisfy this documentation pathway.

    • Standard continuation criteria

      • Diagnosis and specialist requirements: The member has Hunter syndrome (mucopolysaccharidosis type II), and the prescriber is a specialist in genetic or metabolic diseases or specialist consultation notes are provided.
      • Disease confirmation

        • IDS genetic confirmation: Genetic testing confirms a mutation in the IDS gene.
        • Enzyme activity confirmation: An iduronate-2-sulfatase assay confirms reduced or absent activity in serum, white blood cells, or fibroblasts.
      • Weight: The member weighs at least 5 kg.≥ 5 kg
      • No combination with Elaprase: Avlayah and Elaprase will not be used in combination.
      • Treatment and neurologic criteria

        • Elaprase exception: There is an inadequate response, adverse reaction, or contraindication to Elaprase.
        • Neurologic eligibility

          • Neurologic status: The member has neurologic manifestations associated with MPS II or is at risk for neurologic manifestations and is presymptomatic.
          • No advanced neurologic impairment: The member does not have advanced neurologic impairment, including severe cognitive decline, minimal ability to communicate or interact meaningfully, or profound functional dependence.
      • Appropriate dosing: Avlayah is prescribed at an appropriate dose.

    Avlayah and Elaprase must not be used in combination. Coverage criteria require selection of Avlayah without concurrent Elaprase therapy.

    The member must not have advanced neurologic impairment, including severe cognitive decline, minimal ability to communicate or interact meaningfully, or profound functional dependence.

    Coding and Member Requirements

    Minimum member weight
    Minimum member weight≥ 5 kg
    PopulationPediatric patients
    Treatment contextAvlayah is indicated for neurologic manifestations of Hunter syndrome when initiated before advanced neurologic impairment.

    Provider Actions and Authorization Risks

    Prior Authorization

    Medical Benefit Prior Authorization Required

    Prior authorization is required for Avlayah (tividenofusp alfa-eknm) under the MassHealth UPPL. Avlayah is covered under the medical benefit; submit requests through the medical benefit authorization process.

    • Medical benefit phone: 833-895-2611
    • Medical benefit fax: 888-656-6671
    Denial Risk

    Failure to Meet Continuation Criteria

    For members new to the plan, authorization may be denied unless current treatment with Avlayah is documented. Continuation authorization requires the applicable diagnosis, specialist, testing, weight, response or intolerance, neurologic-status, dosing, and non-combination criteria to be met.

    • Diagnosis and disease-confirmation testing must be documented.

    Therapy Background

    Avlayah (tividenofusp alfa-eknm) is a hydrolytic lysosomal glycosaminoglycan-specific enzyme indicated for neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II) in presymptomatic or symptomatic pediatric patients weighing at least 5 kg and before advanced neurologic impairment.

    Key Definitions

    Hunter syndrome
    ConditionMucopolysaccharidosis type II, a lysosomal storage disorder.
    Alternate nameHunter syndrome.
    AbbreviationMPS II.
    Advanced neurologic impairment
    Severe cognitive declineA significant decline in cognitive function.
    Communication or interactionMinimal ability to communicate or interact meaningfully.
    Functional statusProfound functional dependence.

    Avlayah Continuation Authorization

    Avlayah continuation authorization

    For continuation authorization, members new to the plan require current-treatment documentation; otherwise authorization may be granted when all standard continuation criteria are met. Resubmission by the prescriber infers a positive response to therapy.

    Continuation therapy pathways

    • New-to-plan pathway: The member's coverage effective date is less than or equal to 90 days and medical records document current treatment with Avlayah.Coverage effective date ≤ 90 days

      Exclude treatment obtained as samples or through a manufacturer's patient assistance program.

    • Established clinical criteria

      • Hunter syndrome diagnosis: The member has a diagnosis of Hunter syndrome (mucopolysaccharidosis type II).
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyAvlayah continuation therapy
    Policy CodePolicy N/A
    Change TypeAdministrative formatting update
    Effective DateJan 4, 202748d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization under the MassHealth UPPL; Avlayah is covered under the medical benefit.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Member RequirementsProvider Actions and Authorization RisksTherapy BackgroundKey DefinitionsAvlayah Continuation Authorization
  1. The prescriber must be a genetic or metabolic disease specialist, or specialist consultation notes must be provided.
  2. Member weight must be at least 5 kg and appropriate dosing must be documented.
  3. Denial Risk

    Combination Therapy Is Not Allowed

    Authorization may be denied if Avlayah and Elaprase will be used together. Confirm and document that the two therapies will not be administered in combination.

    • Avlayah and Elaprase must not be used in combination.
    Documentation Required

    Current Treatment Records for New Members

    If the member’s coverage effective date is 90 days or less, submit medical records documenting that the member is currently receiving treatment with the requested drug. Treatment obtained as samples or through a manufacturer’s patient assistance program does not satisfy this requirement.

    • Apply this documentation requirement when the coverage effective date is less than or equal to 90 days.
    • Document current treatment with Avlayah; requests may be denied when current treatment is not documented or treatment was interrupted.
    • Do not rely on samples or manufacturer patient assistance program records as evidence of qualifying treatment.
    Documentation Required

    Diagnosis and Disease Confirmation

    Document Hunter syndrome (Mucopolysaccharidosis II), the required specialist involvement, and disease-confirmation evidence. Supporting records must include genetic or enzyme assay testing establishing the diagnosis.

    • Diagnosis: Hunter syndrome (Mucopolysaccharidosis II).
    • Prescriber must specialize in genetic or metabolic diseases, or provide consultation notes from such a specialist.
    • Provide genetic testing confirming a mutation in the IDS gene, or an iduronate-2-sulfatase assay showing reduced or absent activity in serum, white blood cells, or fibroblasts.

    Unsupported block type: documentation

    Denial Risk

    Authorization Denial Risks

    Continuation authorization may be denied when required diagnosis, specialist, disease-confirmation testing, weight, clinical response or neurologic documentation, dosing, or non-combination requirements are missing or unmet. Ensure the record supports every applicable criterion before submitting the request.

    • Hunter syndrome diagnosis must be documented.
    • IDS genetic testing or qualifying iduronate-2-sulfatase assay results must be provided.
    • Specialist prescriber or specialist consultation documentation is required.
    • Weight must be ≥ 5 kg, dosing must be appropriate, and Avlayah must not be combined with Elaprase.
    Specialist involvement: The prescriber is a specialist in genetic or metabolic diseases, or consultation notes from a specialist are provided.
  4. Confirmatory testing

    • IDS genetic confirmation: Genetic testing confirms a mutation in the IDS gene.
    • Enzyme activity confirmation: An iduronate-2-sulfatase assay confirms reduced or absent activity in serum, white blood cells, or fibroblasts.
  5. Weight requirement: The member weighs at least 5 kg.≥ 5 kg
  6. No Avlayah and Elaprase combination: Avlayah and Elaprase will not be used in combination.
  7. Treatment or neurologic pathway

    • Elaprase exception: There is an inadequate response, adverse reaction, or contraindication to Elaprase.
    • Neurologic eligibility

      • Neurologic status: The member has neurologic manifestations associated with MPS II or is at risk for neurologic manifestations and is presymptomatic.
      • No advanced neurologic impairment: The member does not have advanced neurologic impairment, including severe cognitive decline, minimal ability to communicate or interact meaningfully, or profound functional dependence.
  8. Appropriate dosing: Avlayah is prescribed at an appropriate dose.